Alpha-and gamma-msh analogues
AssigneeTXP Pharma GmbH
InventorThomas BOESEN
Life of this patent
Estimating the term…
Abstract
The present invention provides peptide analogues of α-MSH and γ-MSH, comprising the amino acid sequence of human α-MSH or γ-MSH, or variants thereof, and having a branched amino acid probe in the N-terminal part of the peptide.
Claims21
-81. (canceled)
A peptide consisting of from 14 to 16 amino acid residues comprising the amino acid sequence:
- X-(aa1)n-Y-(aa2)m-Z
- wherein X is a branched amino acid probe consisting of 3 lysine residues having the formula Ac-(Ac-Lys-Lys)Lys1-;
- and
- wherein (aa1)n is an amino acid sequence consisting of 4 or 5 contiguous amino acid residues selected from the group consisting of Ser-Tyr-Ser-Met-Glu (SEQ ID NO:17), Ser-Tyr-Ser-Nle-Glu (SEQ ID NO:18), Ser-Ser-Ile-Ile-Ser (SEQ ID NO:19), Tyr-Val-Met-Gly (SEQ ID NO:20) and Tyr-Val-Nle-Gly (SEQ ID NO:21);
- and
- wherein Y is an amino acid sequence consisting of 4 contiguous amino acid residues selected from the group consisting of His-Phe-Arg-Trp (SEQ ID NO:16);
- His-(D-Phe)-Arg-Trp;
- His-Phe-(D-Arg)-Trp;
- His-Phe-Arg-(D-Trp);
- His-(D-Phe)-Arg-(D-Trp);
- His-NaI-Arg-Trp and His-(D-Nal)-Arg-Trp;
- and
- wherein (aa2)m is selected from the group consisting of Gly and Asp;
- and
- wherein Z is an amino acid sequence consisting of 2 or 3 contiguous amino acid residues selected from the group consisting of Lys-Pro-Val;
- Lys-Pro-(D-Val);
- Arg-Phe-Gly;
- Arg-(D-Phe)-Gly;
- Arg-Phe and Arg-(D-Phe);
- wherein said carboxy terminal Val, D-Val, Gly, Phe or D-Phe of Z may optionally be modified by amidation (—NH2).
The peptide according to claim 81, wherein said peptide consists of 16 amino acid residues and (aa1)n is selected from the group consisting of Ser-Tyr-Ser-Met-Glu (SEQ ID NO:17), Ser-Tyr-Ser-Nle-Glu (SEQ ID NO:18), Ser-Ser-Ile-Ile-Ser (SEQ ID NO:19);
- and
- Y is selected from the group consisting of His-Phe-Arg-Trp (SEQ ID NO:16);
- His-(D-Phe)-Arg-Trp;
- His-Phe-(D-Arg)-Trp;
- His-Phe-Arg-(D-Trp);
- His-(D-Phe)-Arg-(D-Trp);
- His-Nal-Arg-Trp and His-(D-Nal)-Arg-Trp;
- and
- (aa2)m is Gly;
- and
- Z is selected from the group consisting of Lys-Pro-Val and Lys-Pro-(D-Val);
- wherein said carboxy terminal Val or D-Val of Z may optionally be modified by amidation (—NH2).
The peptide according to claim 81, wherein said peptide consists of 14 or 15 amino acid residues and (aa1)n is selected from the group consisting of Tyr-Val-Met-Gly (SEQ ID NO:20) and Tyr-Val-Nle-Gly (SEQ ID NO:21);
- and
- Y is selected from the group consisting of His-Phe-Arg-Trp (SEQ ID NO:16);
- His-(D-Phe)-Arg-Trp;
- His-Phe-(D-Arg)-Trp;
- His-Phe-Arg-(D-Trp);
- His-(D-Phe)-Arg-(D-Trp);
- His-Nal-Arg-Trp and His-(D-Nal)-Arg-Trp;
- and
- (aa2)m is Asp;
- and
- Z is selected from the group consisting of Arg-Phe-Gly;
- Arg-(D-Phe)-Gly;
- Arg-Phe and Arg-(D-Phe),
- wherein said carboxy terminal Gly, Phe or D-Phe of Z may optionally be modified by amidation (—NH2).
A pharmaceutical composition comprising the peptide according to claim 81.
A method for treatment of an ischemic and/or inflammatory condition in the tissue of one or more organs, said method comprising the step of administering a therapeutically effective amount of a peptide according to claim 81 to an individual in need thereof.
Dependencies are inferred from the claim text.